Supplementary Figure 3 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Authors :: Gerald Edelman
Coumaran Egile
Yi Xu
Linh T. Nguyen
A. Douglas Laird
Christian Scheffold
Shuchi S. Pandya
Irene Braña
Jose Baselga
Eunice L. Kwak
Cynthia Bedell
Jordi Rodon
Geoffrey I. Shapiro
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 6224K, Inhibition of MEK-ERK pathway signaling in tumor biopsies.

Tools